Sun Pharma Advanced Research Company Ltd. (SPARC) fundamentals
Sun Pharma Advanced Research Company Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SPARC (ISIN INE232I01014). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Sun Pharma Advanced Research Company Ltd. does
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company’s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.
Valuation and market data
| Last close | ₹196.91 |
|---|---|
| Market capitalisation | ₹6,390 crore |
| Enterprise value | ₹6,467 crore |
| P/E (TTM) | 4.11 |
| Price to book | 4.77 |
| Price to sales (TTM) | 3.26 |
| Book value per share | ₹41.25 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jul 18 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,890 crore | ₹1,553 crore | ₹1,553 crore | 47.86 |
| Mar 2025 | ₹74 crore | ₹-343 crore | ₹-343 crore | -10.55 |
| Mar 2024 | ₹105 crore | ₹-387 crore | ₹-387 crore | -11.93 |
| Mar 2023 | ₹250 crore | ₹-223 crore | ₹-223 crore | -7.82 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 65.7% |
|---|---|
| Foreign institutions (FII) | 3.9% |
| Mutual funds | 0.1% |
| Other domestic institutions | 0.0% |
| Retail and others | 30.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.